Compare SPXX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPXX | CDXS |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.9M | 256.3M |
| IPO Year | 2005 | 2008 |
| Metric | SPXX | CDXS |
|---|---|---|
| Price | $17.66 | $2.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 312.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $15.78 | $0.96 |
| 52 Week High | $18.35 | $3.87 |
| Indicator | SPXX | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 65.63 | 66.96 |
| Support Level | $17.67 | $2.37 |
| Resistance Level | $18.18 | $2.83 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 90.74 | 66.13 |
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.